Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration |
| gptkbp:ATCCode |
B01AX07
|
| gptkbp:brand |
Cablivi
|
| gptkbp:CASNumber |
1262842-23-5
|
| gptkbp:developer |
gptkb:Ablynx
|
| gptkbp:hasMolecularFormula |
C646H1000N172O203S4
|
| https://www.w3.org/2000/01/rdf-schema#label |
Caplacizumab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits interaction between von Willebrand factor and platelets
|
| gptkbp:routeOfAdministration |
subcutaneous
intravenous |
| gptkbp:sideEffect |
bleeding
fatigue headache |
| gptkbp:target |
gptkb:von_Willebrand_factor
|
| gptkbp:UNII |
6Y7M6M9H11
|
| gptkbp:usedFor |
acquired thrombotic thrombocytopenic purpura
|
| gptkbp:bfsParent |
gptkb:Ablynx
|
| gptkbp:bfsLayer |
7
|